Nature Communications, 2019 Immunoglobulin Light Chain Amyloidosis (AL) is the most common systemic amyloidosis occurring in Western countries. Here the authors present the 4.0 Å cryo-EM structure of light chain AL55 fibrils that were isolated from the heart of an AL systemic ...
Paolo Swuec +13 more
doaj +2 more sources
Púrpura: manifestação de amiloidose sistémica primária. [PDF]
Acta Médica Portuguesa, 2009 Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Sara Lestre +4 more
doaj +2 more sources
Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis
Acta Haematologica, 2020 Immunoglobulin light chain amyloidosis (AL amyloidosis) is a rare, life-threatening disease characterized by the deposition of misfolded proteins in vital organs such as the heart, the lungs, the kidneys, the peripheral nervous system, and the ...
Layla N. Van Doren, S. Lentzsch
semanticscholar +3 more sources
Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy [PDF]
Case Reports in Gastrointestinal Medicine, 2021 Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart.
Katsuya Endo +15 more
doaj +2 more sources
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. [PDF]
Haematologica, 2018 A 67-year-old male presented with a one-year history of fatigue, cold intolerance, malaise and an unintentional weight loss of ~80 lbs over the course of the preceding 12 months.
Leung N, Thomé SD, Dispenzieri A.
europepmc +2 more sources
99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
European Heart Journal - Cardiovascular Imaging, 2021 Aims Technetium-99m-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD scintigraphy) is recognized as highly accurate for the non-invasive diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA).
C. Quarta +15 more
semanticscholar +4 more sources
Recent advances in understanding and treating immunoglobulin light chain amyloidosis [version 1; referees: 2 approved] [PDF]
F1000Research, 2018 Immunoglobulin (Ig) light chain (AL) amyloidosis is a clonal plasma cell disorder characterized by misfolded Ig light chain deposition in vital organs of the body, resulting in proteotoxicity and organ dysfunction.
Talha Badar +2 more
doaj +2 more sources
Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting. [PDF]
J Hematol OncolBu Q, Zhu HH, Chen W.
europepmc +2 more sources
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
American journal of hematology/oncology, 2022 Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar +1 more source
Systemic Immunoglobulin Light Chain Amyloidosis Involving the Large Intestine. [PDF]
ACG Case Rep J, 2021 ABSTRACT Amyloidosis is characterized by extracellular tissue deposition of fibrils resulting in disruption of tissue structure and function. Gastrointestinal amyloidosis commonly results from chronic inflammatory disorders (amyloid A amyloidosis) and is less commonly seen in immunoglobulin light chain amyloidosis. We present a rare case of a
Swaminathan R, Igbinedion S, Pandit S.
europepmc +3 more sources